In this investigation, we characterized the activity and mechanism of TPST-1495, a first-in-class dual antagonist which specifically inhibits signaling through the tumor-promoting EP2 and EP4 PGE2 receptors and allows for continued of PGE2 signaling through the immune-promoting EP1 and EP3 receptors. This evidence concerns the gene PTGER2 and neoplasm.